As patent cliff levels off, biosimilars offer opportunity

09/11/2013 | Drug Store News

About $86 billion worth of branded drugs will lose patent protection between 2013 and 2017, compared with $101 billion worth of drugs that lost patent protection between 2008 and 2012, according to IMS. Biologic drugs losing patent protection may present an opportunity for other drugmakers to gain market share, but some U.S. states have passed laws restricting substitution of biosimilar drugs.

View Full Article in:

Drug Store News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY